← The Wire
RGNXNasdaq
REGENXBIO Inc.
Biological Products, (No Diagnostic Substances) · CIK 1590877
Develops gene therapy treatments using its NAV Technology Platform for genetic defects and therapeutic protein production
⚡ Elevated coverage
$344M
Market cap
$11.83
Last close
+12.9%
1D
+30.4%
5D
2.5M
Volume
Price · last 39 sessions+26.0%
May 4L $5.65 · H $11.83Jun 29
215
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
DEF 14ADEF 14AApr 14, 2026DEF 14ADEF 14AApr 8, 2025DEF 14ADEF 14AApr 4, 2024DEF 14ADEF 14AApr 6, 2023DEF 14ADEF 14AApr 7, 2022DEF 14ADEF 14AApr 19, 2021DEF 14ADEF 14AApr 8, 2020DEF 14ADEF 14AApr 11, 2019DEF 14ADEF 14AApr 12, 2018DEF 14ADEF 14AApr 13, 2017DEF 14ADEF 14AApr 18, 2016
Insider Activity
In the 90 days to Mar 10, 2026: 1 sold $53K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 | Pakola SteveChief Medical Officer | Sell | 5,124 | $10.35 | $53K |
| Oct 9, 2025 | Simpson CurranChief Executive Officer | Sell | 20,811 | $12.62 | $263K |
| Sep 29, 2025 | Simpson CurranChief Executive Officer | Sell | 7,624 | $10.03 | $76K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance